echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > The third party evaluation system of Shanghai drug purchase will be put into trial operation next week

    The third party evaluation system of Shanghai drug purchase will be put into trial operation next week

    • Last Update: 2018-04-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: medical geography 2017-4-23 according to medical geography, the third-party evaluation system for drug procurement developed by China Pharmaceutical Industry Information Center will be put into trial operation next week During the trial operation, it is mainly open to medical institutions and some enterprises Relying on the data platform of China Pharmaceutical Industry Information Center and Shanghai Sunshine pharmaceutical procurement platform, the third-party evaluation system of pharmaceutical procurement provides 100% objective and authoritative data services Through the analysis and publicity of drug purchase data of medical institutions, we can solve the problem of centralized drug purchase in medical institutions in an open and market-oriented way, and connect the government, hospitals and pharmaceutical enterprises at the same time, which provides an important starting point for sunshine purchase The reporter learned that the system is composed of two dimensions: drugs and enterprises From the drug dimension, price level, technology level, clinical applicability and market share are the main indicators; while the enterprise dimension is to comprehensively consider its technological innovation ability, drug supply capacity, quality management level, social responsibility and credibility The results will provide a basis for medical institutions in clinical use of drugs, and also provide a regulatory reference for the government, which can detect abnormal purchasing behavior in time In recent years, with the gradual decentralization of drug purchase autonomy, industry self-discipline has become an important melody of the pharmaceutical industry, "play the decisive role of the market in the allocation of resources" is gradually implemented in a series of behaviors such as drug purchase, which puts forward higher requirements for the supervision work in the new era How to better accept the supervision of the masses and improve the bargaining power has become an urgent issue for pharmaceutical enterprises As the first city to implement the consistency evaluation drug purchase, on February 2, Shanghai publicized the basic information of the declared varieties through the sunshine medicine purchase network to the society, pointing out that the publicized varieties can be purchased by the medical institutions after the drug manufacturers and medical institutions negotiate the transaction price through the inquiry and price negotiation system in the "sunshine platform" This measure links procurement with conformity evaluation and encourages the promotion of conformity evaluation On April 19, the second batch of generic drugs (including 8 varieties and 19 specifications) passed the consistency evaluation of quality and efficacy in Shanghai In addition to the previously released 3 varieties and 5 specifications, a total of 11 varieties and 24 specifications took effect in Shanghai However, the drug price increased slightly through consistency evaluation This indicates that under multiple measures, drug purchase will be more directly equal to "high quality and good price", and the future price negotiation trend will be more clear This time, the launch of the third-party evaluation system for drug procurement in Shanghai changed the single evaluation mode of "only taking low price", promoted medical institutions to choose "good drugs" on the basis of "cost control", reduced the impact of price factors on their procurement behavior, and promoted the cost-effectiveness of drugs It also helps high-quality enterprises and drugs get reasonable profit guarantee In response, many enterprises and medical institutions applauded, "the exchange and sharing of data enables drugs with high cost performance and high market acceptance to be automatically screened, eliminates the phenomenon of information island, and guides benign market competition." Many companies said For the impact of this evaluation system, relevant people pointed out that "it will not have an impact on drug market access, and if problems are found, there will be no corresponding administrative penalty But it is a kind of "backward force" means, which is a good guide to purchasing behavior " It is said that in the later stage, the public version of "my medicine review" system will be launched, which will be opened to the public through the website to rationalize the star rating of drugs, not only to meet the confidentiality of sensitive commercial data, but also to meet the public's right to know, which will help to alleviate the Doctor-patient Conflict to a certain extent.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.